We have updated our Terms of Use.
Please read our new Privacy Statement before continuing.

Navel gazing

28 January 2021 By Robyn Mak

The pharma giant is planning to take Hong Kong-listed China Traditional Chinese Medicine private in a $3.3 bln deal. The market’s growth, high margins and political support justify the premium. Relisting on the mainland at a richer valuation will be good for shareholders’ health.

This content is for Subscribers only

 

Email a friend

Please complete the form below.

Required fields *

*
*
*

(Separate multiple email addresses with commas)